Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of RAD001 (Afinitor, everolimus) in advanced thyroid carcinoma
2009-016669-27Phase 2Active
- Sponsor
- Leiden University Medical Center
- Start
- Jan 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of everolimus in well-differentiated thyroid cancer (WDTC) and Medullary Thyroid Cancer (MTC), sponsored by Leiden University Medical Center. Primary endpoints: Tumor response rate and Maximum percentage of tumor reduction. Started Jan 2010; status: active.
02
Drugs
everolimus
03
Conditions
well-differentiated thyroid cancer (WDTC)Medullary Thyroid Cancer (MTC)
Beyond the preview
Go deeper on 2009-016669-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-016669-27.